Teladoc Inc
$ 6.66
0.45%
05 May - close price
- Market Cap 1,196,802,000 USD
- Current Price $ 6.66
- High / Low $ 6.80 / 6.55
- Stock P/E N/A
- Book Value 7.77
- EPS -29.87
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.12 %
- 52 Week High 9.77
- 52 Week Low 4.40
About
Teladoc Health, Inc. provides business-to-business virtual health care services in the United States and internationally. The company is headquartered in Purchase, New York.
Analyst Target Price
$7.10
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-31 | 2026-02-24 | 2025-10-29 | 2025-07-29 | 2025-04-23 | 2025-02-18 | 2024-10-30 | 2024-07-31 | 2024-04-25 | 2024-02-20 | 2023-10-24 | 2023-07-25 |
| Reported EPS | -0.2836 | -0.1034 | -0.28 | -0.1473 | -0.2188 | -0.2451 | -0.19 | -0.28 | -0.49 | -0.17 | -0.35 | -0.4 |
| Estimated EPS | -0.3867 | -0.1813 | -0.2572 | -0.2632 | -0.358 | -0.2933 | -0.28 | -0.35 | -0.46 | -0.21 | -0.37 | -0.41 |
| Surprise | 0.1031 | 0.0779 | -0.0228 | 0.1159 | 0.1392 | 0.0482 | 0.09 | 0.07 | -0.03 | 0.04 | 0.02 | 0.01 |
| Surprise Percentage | 26.6615% | 42.9675% | -8.8647% | 44.035% | 38.8827% | 16.4337% | 32.1429% | 20% | -6.5217% | 19.0476% | 5.4054% | 2.439% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TDOC
2026-05-05 05:17:49
The report by Coherent Market Insights analyzes the Ehealth Market from 2026 to 2033, featuring key players like Teladoc Health, Amwell, and Cerner Corporation. It provides detailed insights into market dynamics, competitive landscape, regional performance, and growth opportunities through segmentation analysis and competitive benchmarking. The study aims to equip stakeholders with actionable intelligence for strategic decision-making in the evolving eHealth sector.
2026-05-05 04:09:49
Teladoc Health (TDOC) reported mixed Q1 results, with revenue rising but net loss attributable to the company increasing. The company provided a weak Q2 revenue outlook, forecasting a range of $635 million to $645 million, below analyst estimates, but reaffirmed its full-year revenue guidance.
2026-05-04 14:09:07
Teladoc Health (TDOC) reported a first-quarter 2026 adjusted loss of 36 cents per share, missing consensus estimates, and revenues declined 2% year over year to $613.8 million due to weakness in its BetterHelp segment and decreasing subscription revenues. Despite the overall decline, the Integrated Care segment showed growth, and international revenues increased. The company also provided its outlook for Q2 and the full year 2026, anticipating continued challenges for BetterHelp but some growth in Integrated Care.
2026-05-04 13:09:49
Teladoc Health (TDOC) has seen recent share price rebounds of 12.3% over 7 days and 22.6% over 30 days, despite multi-year losses. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 46.5%, implying an intrinsic value of US$12.07 per share compared to its current price of US$6.46. Additionally, its Price/Sales ratio of 0.46x is significantly below the industry average, further indicating undervaluation.
2026-05-03 08:38:58
Teladoc Health (TDOC) has seen a recent share price rebound, with returns of 12.3% over 7 days and 22.6% over 30 days, despite multi-year losses. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 46.5%, with an estimated intrinsic value of US$12.07 per share compared to its current price of US$6.46. The article also presents bull and bear case narratives for Teladoc, with fair values ranging from US$5.00 to US$10.50 per share, based on different assumptions about revenue growth, market conditions, and profitability.
2026-05-03 05:38:58
Teladoc Health reported Q1 2026 results, exceeding revenue estimates at $613.8 million despite a 2.5% year-over-year decline. The company's adjusted EBITDA surpassed projections, and it reconfirmed full-year revenue and GAAP EPS guidance, while Q2 guidance came in below expectations. Management attributed performance and future guidance to a shift towards visit-based models, expanded insurance coverage for BetterHelp, and leveraging AI for efficiency and product enhancement.
